JP2021534802A5 - - Google Patents

Info

Publication number
JP2021534802A5
JP2021534802A5 JP2021511646A JP2021511646A JP2021534802A5 JP 2021534802 A5 JP2021534802 A5 JP 2021534802A5 JP 2021511646 A JP2021511646 A JP 2021511646A JP 2021511646 A JP2021511646 A JP 2021511646A JP 2021534802 A5 JP2021534802 A5 JP 2021534802A5
Authority
JP
Japan
Prior art keywords
cancer
seq
domain
antigen
cell
Prior art date
Application number
JP2021511646A
Other languages
English (en)
Japanese (ja)
Other versions
JP7394840B2 (ja
JP2021534802A (ja
JPWO2020043899A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/073257 external-priority patent/WO2020043899A1/en
Publication of JP2021534802A publication Critical patent/JP2021534802A/ja
Publication of JP2021534802A5 publication Critical patent/JP2021534802A5/ja
Publication of JPWO2020043899A5 publication Critical patent/JPWO2020043899A5/ja
Application granted granted Critical
Publication of JP7394840B2 publication Critical patent/JP7394840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511646A 2018-08-31 2019-08-30 複数のｈｌａ－ｇアイソフォームに対するキメラ抗原レセプター Active JP7394840B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18306153.0 2018-08-31
EP18306153 2018-08-31
EP19305809 2019-06-21
EP19305809.6 2019-06-21
PCT/EP2019/073257 WO2020043899A1 (en) 2018-08-31 2019-08-30 Chimeric antigen receptors against multiple hla-g isoforms

Publications (4)

Publication Number Publication Date
JP2021534802A JP2021534802A (ja) 2021-12-16
JP2021534802A5 true JP2021534802A5 (https=) 2022-09-07
JPWO2020043899A5 JPWO2020043899A5 (https=) 2022-09-07
JP7394840B2 JP7394840B2 (ja) 2023-12-08

Family

ID=67766182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511646A Active JP7394840B2 (ja) 2018-08-31 2019-08-30 複数のｈｌａ－ｇアイソフォームに対するキメラ抗原レセプター

Country Status (12)

Country Link
US (5) US11117971B2 (https=)
EP (1) EP3843778A1 (https=)
JP (1) JP7394840B2 (https=)
KR (1) KR20210112295A (https=)
CN (1) CN112912105B (https=)
AU (1) AU2019328677A1 (https=)
BR (1) BR112021003757A2 (https=)
IL (1) IL281097A (https=)
MX (1) MX2021002316A (https=)
SG (1) SG11202101849XA (https=)
WO (1) WO2020043899A1 (https=)
ZA (1) ZA202101358B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms
CR20210197A (es) 2018-09-27 2021-06-03 Tizona Therapeutics Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
EP4079846A1 (en) * 2021-04-23 2022-10-26 SVAR Life Science AB Novel luciferases with improved properties
EP4347635A4 (en) * 2021-05-26 2025-07-09 Univ Texas CHIMERIC ANTIGEN RECEPTOR TO TARGET HLA-G POSITIVE CANCERS
TWI823402B (zh) * 2021-07-21 2023-11-21 長聖國際生技股份有限公司 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物
KR20240038974A (ko) * 2021-07-29 2024-03-26 난트셀, 인크. 바이러스 감염 및 암의 예방 및 치료를 위한 변형된 t 세포 수용체
US12594344B2 (en) * 2021-12-03 2026-04-07 China Medical University Production of exosomes and uses thereof
CN114380920B (zh) * 2021-12-17 2024-06-28 广州达安基因股份有限公司 人甲胎蛋白融合蛋白及其制备方法和应用
CN114605543B (zh) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
CN119053618A (zh) 2022-02-04 2024-11-29 恩基尔特医疗有限公司 嵌合ilt受体组合物和方法
AU2023238456A1 (en) * 2022-03-25 2024-10-17 Hk Inno.N Corporation Anti-hla-g chimeric antigen receptor, and use thereof
CN115112900B (zh) * 2022-06-15 2024-08-16 四川大学华西医院 检测脂解激活脂蛋白受体的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途
CN119768507A (zh) * 2022-06-24 2025-04-04 怡诺安有限公司 表达免疫检查点调节剂的免疫细胞及其用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
CN120583960A (zh) * 2022-11-28 2025-09-02 英韦克泰斯公司 人源化抗hla-g嵌合抗原受体及其用途
CN116535500B (zh) * 2022-11-30 2024-03-22 西南大学 马铃薯x病毒单克隆抗体pvx-6及其应用
CN119569892A (zh) * 2023-09-06 2025-03-07 上海恩凯细胞技术有限公司 特异性靶向肿瘤非经典hla分子的嵌合抗原受体的应用
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用
WO2025080055A1 (ko) * 2023-10-12 2025-04-17 주식회사 아이엠바이오로직스 Hla-g에 특이적으로 결합하는 항체 및 이의 용도
CN118420786B (zh) * 2024-06-12 2025-10-17 浙江大学医学院附属第一医院(浙江省第一医院) 一种靶向her2和hla-g的双特异性嵌合抗原受体及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
EP0819171A1 (en) 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
DE60226852D1 (de) 2001-03-13 2008-07-10 Novartis Ag Lentivirale verpackungskonstrukte
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
PT3294764T (pt) * 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
NZ748929A (en) * 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
JP2020501512A (ja) 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AU2019328677A1 (en) 2018-08-31 2021-04-01 Invectys SA Chimeric antigen receptors against multiple HLA-G isoforms
TWI694083B (zh) 2018-09-17 2020-05-21 中國醫藥大學附設醫院 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物

Similar Documents

Publication Publication Date Title
JP2021534802A5 (https=)
JPWO2020043899A5 (https=)
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
EP4039707A1 (en) Cd3-targeting antibody, bispecific antibody and use thereof
US20220226469A1 (en) Therapeutic sirp-alpha antibodies
JP2020501531A5 (https=)
JP2019500892A5 (https=)
JP2018503380A5 (https=)
JP2016536020A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
HRP20240415T1 (hr) Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba
JPWO2020135201A5 (https=)
JP2019512207A5 (https=)
JP2021520201A5 (https=)
JP7392145B2 (ja) 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム
CA3068932A1 (en) Bispecific anti pd1-anti tim3 antibodies
CN112292399A (zh) 抗cd27抗体及其用途
CN114524878A (zh) 一种双特异性抗体及其用途
JP2020528936A5 (https=)
JP2024001073A5 (https=)
EP3947456A1 (en) Cd3 binding molecules
JP7730432B2 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
JPWO2020076799A5 (https=)
JPWO2019195452A5 (https=)
IL321677A (en) Anti-PDL1 antibodies, multispecific antibodies, and methods of use